<DOC>
	<DOCNO>NCT00923650</DOCNO>
	<brief_summary>Background : - Informed consent process prospective participant clinical trial learn clinical research order decide whether want enroll study . It consist meeting discussion health care team . - Phase I clinical trial design determine dose investigational agent safe administer patient . Objectives : - To study communication , comprehension decision-making informed consent process . - To examine ethical , psychological , social , educational issue regard informed consent . - To help researcher understand improve informed consent education clinical research . Eligibility : - Parents guardians child cancer consider participation phase I clinical trial - Prospective patient pediatric phase I clinical trial 14 21 year age . - Members research team obtain consent patient family pediatric phase I clinical trial Design : - Research assistant observe record inform consent conference hold research team parent child . - After conference , research assistant interview parent private area experience conference decision-making process . They ask thought opinion inform consent conference , include decision-making process , communication trust medical team . - With parent 's permission , patient interview privately discuss experience inform consent conference . - After parent patient make decision participation study , interview make decision , aspects communication conference , feel doctor . This interview also record . - Parents may contact 6 month 2 year time participation part parent advisory group inform consent process .</brief_summary>
	<brief_title>Informed Consent Pediatric Cancer Trials</brief_title>
	<detailed_description>Background : - The clinical course poor prognosis child adolescent eligible pediatric phase I trials may increase vulnerability patient family confound inform consent - Physicians report tension present reasonable option truthful prognosis maintain hope . - Research communication decision regard participation pediatric phase I trial need . Objectives : - The primary objective study understand communication , comprehension , decision-making Phase I childhood cancer trial ( Specific Aim 1 ) examining : - The way phase I pediatric trial present ( Aim 1 Hypothesis 1 ) - Whether alternative ( hospice ) introduce ( Aim 1 Hypothesis 2 ) - What parent child old 14 year understand consent discussion ( Aim 1 Hypothesis 3 ) - How communication process influence parental comprehension decision-making regard participation child phase I study ( Aim 1 Hypothesis 4 ) - How clinician-investigator perspective may vary parent child participate phase I study ( Aim 1 Hypothesis 5 ) - Compare Phase I vs . Phase III pediatric cancer inform consent ( Specific Aim 2 ) regarding : - Parental understanding scientific goal trial ( Aim 2 Hypothesis 1 ) - Trust , decision making preference , strength recommendation investigator interactivity measure number parental question , reason decision , child 's involvement , read consent document , parental understanding choice trial design/purpose , disclosure prognosis ( Aim 2 Hypothesis 1-9 ) - Develop suggestion intervention improve inform consent Phase I pediatric cancer trial Parent Advisory Group Informed Consent ( PAGIC ) . ( Specific Aim 3 ) Eligibility : - Parents guardians child adolescent consider enrollment Phase I Trials anti-cancer agent , gene transfer vaccine study eligible child adolescent le 22yrs diagnosed recurrent refractory malignant solid tumor leukemia . - Participants must speak English Spanish . - Parents guardians child adolescent newly diagnose cancer previously participate informed consent research exclude . - In addition , plan interview small number patient 14-21 year age participate informed consent conference Phase I cancer trial . Design : - Parents ( n=132 ) child adolescent ( age less equal 21 year ) offer participation Phase I clinical trial cancer sequentially recruit . - The method include direct observation , digital recording ICC , questionnaires parent/guardian , patient , health care team member . Research Assistants ( RAs ) train observe record interaction family clinician relate Phase I clinical trial . Children 14 year old interview use separate instrument - Data analyze quantitative qualitative analytic method . To assure 120 case analysis , total accrual 132 case six institution , 100 accrue NCI .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<criteria>INCLUSION CRITERIA : Parent/Guardian : Patient must less equal 21 year age time consent . Parent/guardian must consider child participate Phase I treatment trial Parents must able speak English Spanish Must sign inform consent participation study Patients great equal to14 year age less equal 18 year age : Must consider participate Phase I treatment trial Must able speak English Spanish Must assent participation study Patients great equal 18 year old : Must consider participate Phase I treatment trial Must able speak English Spanish Must sign inform consent participation study , include consent interview parent/guardian , available Heath Care Team Members : Must great equal 18 year age Must speak English Spanish Must sign inform consent document participation study ( write consent obtain annually heath care team member ) Verbal assent participate individual consent conference EXCLUSION CRITERIA : Patients newly diagnose offer participation Phase I trial standard therapy exist disease Patients/Parents previously participate informed consent research conduct Cleveland Clinic Foundation Department Bioethics Families speak English Spanish</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2, 2010</verification_date>
	<keyword>Informed Consent</keyword>
	<keyword>Pediatric Phase I Clinical Trials</keyword>
	<keyword>Assent</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Osteosarcoma</keyword>
	<keyword>Ewing 's Sarcoma</keyword>
	<keyword>Neuroblastoma</keyword>
	<keyword>Brain Tumors</keyword>
	<keyword>Leukemia</keyword>
</DOC>